Cipla receives final approval for generic version of Pfizer’s Depo-Provera® (Medroxyprogesterone Injectable, 150mg/mL)

Deepthi | Myequity news | Date : 28-01-2019 10:25:00 IST

Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).

Cipla’s Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer’s Depo-Provera®. It is a progestin indicated only for the prevention of pregnancy. According to IQVIA (IMS Health), Depo-Provera® and its generic equivalents had US sales of approximately $159M for the 12-month period ending November 2018.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets.

More from Myequity